Aurobindo acquires Lannett – the US Drugmaker for $250 million thereby shoring up the Indian drugmaker’s footprint in the US in the middle of the threats that the Trump administration plans so as to impose tariffs when it comes to foreign-made drugs.
The deal, which is anticipated to get completed in the next 12 months, also happens to give Aurobindo an entry in the attention-deficit/hyperactivity disorder (ADHD) medication segment, where it had no presence before, the company said in a financial filing recently. Apparently, as Aurobindo acquires Lannett, the acquisition goes on to strengthen formers ability to serve the US generic space and also offers strategic diversification when it comes to a specialized and high-value therapeutic segment.
Interestingly, the deal with Lannett – a company founded in 1942—happens to include a 425,000 ft.² manufacturing facility, which is based in Indiana’s Seymour and has the capacity to produce capsules, tablets, and powders, as well as liquids.
It is well to be noted that the facility happens to have the annual capacity of almost 3.6 billion tablets and employs around 435 workers. This purchase syncs well with the initiatives as well as the government requirement preferences, as per Aurobindo’s filing.
Interestingly, Lannett is known for manufacturing-controlled substances – mainly the ADHD medicines along with generic liquids. Notably, the overall market for ADHD medicine was somewhere around 15 billion in 2024 and is anticipated to reach almost 19 billion by the end of the decade.
